Depression remains one of the leading disease conditions with prevalence at 6.4% of the population (16.5 million estimated persons in the US)1. It ranks 2nd largest therapeutic class in the US by prescription in 20102. WHO estimates that by 2030 Depression will be the single biggest burden of disease3 out of all medical conditions.
Even with the availability of a plethora of anti-depressants, two-thirds of patients achieve partial or no remission of their symptoms4.
MDD Universe
Although the current re-uptake inhibiting anti-depressants tolerate better than earlier therapies, significant adverse reactions such as sexual dysfunction, insomnia and weight gain significantly affect compliance among patients. Additional problem with the current anti-depressants is their slow onset of action, requiring at least 6 weeks of treatment to obtain efficacy.
Serdaxin exhibits the potential to address these unmet medical needs in depression with a new mechanism of action that addresses both a negative mood state and loss of positive mood state.
- National Survey on Drug Use and Health report, May 14, 2009.
- Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci. 2002 July; 27(4): 241–247; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC161658/?tool=pmcentrez
- Report by the IMS Institute for Healthcare Informatics, April 2011.
- DALYs = Disability Adjusted Life Years. The sum of years of potential life lost due to premature mortality and the years of productive life lost due to disability.
